These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19285313)

  • 1. Theoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage.
    Wang X; Erickson AM; Allen MR; Burr DB; Martin RB; Hazelwood SJ
    J Biomech; 2009 May; 42(7):938-44. PubMed ID: 19285313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage.
    Li J; Mashiba T; Burr DB
    Calcif Tissue Int; 2001 Nov; 69(5):281-6. PubMed ID: 11768198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs.
    Mashiba T; Hui S; Turner CH; Mori S; Johnston CC; Burr DB
    Calcif Tissue Int; 2005 Sep; 77(3):180-5. PubMed ID: 16265598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate.
    Allen MR; Iwata K; Phipps R; Burr DB
    Bone; 2006 Oct; 39(4):872-9. PubMed ID: 16765660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
    Eisman JA; Cortet B; Boolell M; Ionescu-Ittu R; Vekeman F; Heroux J; Thomasius F
    Osteoporos Int; 2023 May; 34(5):977-991. PubMed ID: 36872338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment.
    Allen MR; Burr DB
    J Bone Miner Res; 2007 Nov; 22(11):1759-65. PubMed ID: 17663638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risedronate: a new oral bisphosphonate.
    Umland EM; Boyce EG
    Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.
    Berto P; Maggi S; Noale M; Lopatriello S
    Aging Clin Exp Res; 2010 Apr; 22(2):179-88. PubMed ID: 20145427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone.
    Allen MR; Erickson AM; Wang X; Burr DB; Martin RB; Hazelwood SJ
    Calcif Tissue Int; 2010 Jan; 86(1):67-71. PubMed ID: 19953232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD; Möller G
    Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A theoretical analysis of long-term bisphosphonate effects on trabecular bone volume and microdamage.
    Nyman JS; Yeh OC; Hazelwood SJ; Martin RB
    Bone; 2004 Jul; 35(1):296-305. PubMed ID: 15207770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
    Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
    Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.
    Mashiba T; Hirano T; Turner CH; Forwood MR; Johnston CC; Burr DB
    J Bone Miner Res; 2000 Apr; 15(4):613-20. PubMed ID: 10780852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
    Katayama K; Matsuno T
    Clin Drug Investig; 2008; 28(3):149-58. PubMed ID: 18266400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.
    Miller PD; Delmas PD; Lindsay R; Watts NB; Luckey M; Adachi J; Saag K; Greenspan SL; Seeman E; Boonen S; Meeves S; Lang TF; Bilezikian JP;
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3785-93. PubMed ID: 18682511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
    Iwamoto J; Takeda T; Sato Y
    Expert Opin Pharmacother; 2007 Nov; 8(16):2743-56. PubMed ID: 17956196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.